Frailty Prevalence and Association with Clinical Outcomes in Interstitial Lung Disease, Asthma, and Pleural Disease.
Idiopathic Pulmonary Fibrosis
asthma
frailty
hospitalisations
interstitial lung disease
mortality
pleural disease
prevalence
Journal
Geriatrics (Basel, Switzerland)
ISSN: 2308-3417
Titre abrégé: Geriatrics (Basel)
Pays: Switzerland
ID NLM: 101704019
Informations de publication
Date de publication:
13 Aug 2023
13 Aug 2023
Historique:
received:
19
07
2023
revised:
09
08
2023
accepted:
11
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Frailty is a syndrome characterised by increased vulnerability to negative outcomes. Interstitial lung disease (ILD), asthma, and pleural disease are leading causes of morbidity and mortality. We aimed to investigate the prevalence and impact of frailty in adult patients with these diseases. We conducted a systematic review and meta-analysis, searching PubMed, Web of Science, The Cochrane Library, and EMBASE for studies reporting on frailty in ILD, asthma, and pleural disease. MeSH terms including interstitial lung disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia, Chronic Hypersensitivity Pneumonitis, systemic sclerosis-associated ILD, connective tissue disease-associated ILD, and frailty were used as key words. The primary outcome was prevalence of frailty. Where enough contextually homogeneous studies were included, a pooled random-effects meta-analysis was performed with mortality and hospitalisation as the outcomes. The review found three studies relating to frailty in asthma. No studies relating to pleural disease and frailty were identified. The median prevalence in asthma was 9.5% (IQR, 7.8-11.3). Six relevant studies incorporating 1471 ILD patients (age 68.3 ± SD2.38; 50% male) were identified, which were either cohort or cross-sectional design rated either good or fair. The median prevalence of frailty was 48% (IQR, 25-50). There was a positive association between frail ILD patients and increased risk of long-term mortality (pooled OR, 2.33 95%CI 1.31-4.15, Frailty is very common and associated with increased mortality in patients with ILD. There are still minimal data regarding the prevalence of frailty and its influence on the risk in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Frailty is a syndrome characterised by increased vulnerability to negative outcomes. Interstitial lung disease (ILD), asthma, and pleural disease are leading causes of morbidity and mortality. We aimed to investigate the prevalence and impact of frailty in adult patients with these diseases.
METHODS
METHODS
We conducted a systematic review and meta-analysis, searching PubMed, Web of Science, The Cochrane Library, and EMBASE for studies reporting on frailty in ILD, asthma, and pleural disease. MeSH terms including interstitial lung disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia, Chronic Hypersensitivity Pneumonitis, systemic sclerosis-associated ILD, connective tissue disease-associated ILD, and frailty were used as key words. The primary outcome was prevalence of frailty. Where enough contextually homogeneous studies were included, a pooled random-effects meta-analysis was performed with mortality and hospitalisation as the outcomes.
RESULTS
RESULTS
The review found three studies relating to frailty in asthma. No studies relating to pleural disease and frailty were identified. The median prevalence in asthma was 9.5% (IQR, 7.8-11.3). Six relevant studies incorporating 1471 ILD patients (age 68.3 ± SD2.38; 50% male) were identified, which were either cohort or cross-sectional design rated either good or fair. The median prevalence of frailty was 48% (IQR, 25-50). There was a positive association between frail ILD patients and increased risk of long-term mortality (pooled OR, 2.33 95%CI 1.31-4.15,
CONCLUSIONS
CONCLUSIONS
Frailty is very common and associated with increased mortality in patients with ILD. There are still minimal data regarding the prevalence of frailty and its influence on the risk in this population.
Identifiants
pubmed: 37623275
pii: geriatrics8040082
doi: 10.3390/geriatrics8040082
pmc: PMC10454934
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
ERJ Open Res. 2022 Oct 17;8(4):
pubmed: 36267896
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Nihon Ronen Igakkai Zasshi. 2011;48(5):545-52
pubmed: 22323034
PLoS One. 2022 Jul 14;17(7):e0270921
pubmed: 35834436
Age Ageing. 2018 Mar 1;47(2):193-200
pubmed: 29040347
Am J Epidemiol. 2017 Aug 15;186(4):420-434
pubmed: 28633404
Ageing Res Rev. 2016 Mar;26:53-61
pubmed: 26674984
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
CMAJ. 2011 May 17;183(8):E487-94
pubmed: 21540166
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Respirology. 2021 Jul;26(7):683-689
pubmed: 33876511
Eur J Intern Med. 2018 Oct;56:49-52
pubmed: 29526651
Respirology. 2017 May;22(4):728-734
pubmed: 27860036
Respir Med. 2017 Aug;129:1-7
pubmed: 28732817
J Frailty Aging. 2017;6(4):219-223
pubmed: 29165541
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Respir Med. 2019 Mar;148:6-12
pubmed: 30827476
Eur Respir J. 2021 Dec 31;59(1):
pubmed: 34667060
BMJ Open Respir Res. 2020 Feb;7(1):
pubmed: 32066563
ScientificWorldJournal. 2001 Aug 08;1:323-36
pubmed: 12806071
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Curr Opin Pulm Med. 2020 Sep;26(5):449-456
pubmed: 32701668
N Engl J Med. 2020 Sep 3;383(10):958-968
pubmed: 32877584
Mol Aspects Med. 2016 Aug;50:1-32
pubmed: 27370407
Curr Opin Pulm Med. 2022 Jul 1;28(4):321-336
pubmed: 35749798
Eur Respir J. 2020 Jan 23;55(1):
pubmed: 31537699
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
Clin Respir J. 2021 Feb;15(2):216-224
pubmed: 33090699